Skip to main content

cCRADA Collaborations: Tailored Solutions for Nano-related Research and Development

The Nanotechnology Characterization Laboratory (NCL) has amassed a large knowledge base on the multitude of available nanoparticle platforms, characterization techniques and their nuances, and nanoparticle biocompatibility throughout its 15+ years providing characterization as part of the Assay Cascade program. NCL now leverages this expertise to conduct sponsor-funded research and development for applications that fall outside of the Assay Cascade constraints, called contractor Cooperative Research and Development Agreement (cCRADA).

While the Assay Cascade is restricted to characterization of oncology-based nanomedicines, cCRADA collaborations are not. These projects can involve non-oncology nanomaterials, such as nanomedicines for other health indications or environmental nanoparticles, mechanistic investigations not covered by the Assay Cascade testing, nanotech formulation projects and more. All cCRADA projects are highly customized and will have a specifically tailored research plan developed in collaboration with the sponsor.

What We Offer

  • Formulation, optimization, lead selection. Design and production of nanoformulations to achieve intended biological endpoints. Experience with small molecules, biologics, vaccines, and gene therapies.
  • Mechanistic studies. In vitro and in vivo studies to identify pharmacological or toxicological mechanisms.
  • Non-oncology nanomaterials. Nanomedicines for other therapeutic indications, environmental, health, and safety characterization of engineered nanomaterials, etc.
  • Bioanalytical assay development. Development and validation of assays for lot release, biological activity, bioequivalence, and more.
  • Instrument optimization. NCL works with instrument developers to improve analytical tools to best meet the needs of the nanotech research community.
  • And more...Contact us at ncl@mail.nih.gov to see how we can help.

cCRADA Process

Projects are considered for cCRADAs on a case-by-case basis throughout the year, taking into consideration NCL’s capabilities and resources, alignment with NCL and NCI’s research interests, and potential impact towards improving nanomedicine research and development.

Interested parties can reach out to the NCL at ncl@mail.nih.gov to discuss their project needs.

For approved projects, a joint statement of work will be collaboratively agreed upon, and NCL will provide a budget for the estimated project costs. Work will be initiated through a cCRADA with Leidos Biomedical Research, Inc., the operations and technical support contractor for the Frederick National Lab.

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “cCRADA Collaborations: Tailored Solutions for Nano-related Research and Development was originally published by the National Cancer Institute.”